Zacks Investment Research upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) from a sell rating to a hold rating in a report released on Monday morning, Zacks.com reports. According to Zacks, “Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved […]
